Circulating CA 549 and Other Associated Antigens in Breast Cancer Patients

Abstract

The new marker CA 549 was determined in the serum of 258 breast cancer patients, classified according to TNM (148 at diagnosis and 110 at relapse), using a RIA method (cut-off: 10 U/ml). CEA, CA 15-3 and MCA were also evaluated. At diagnosis, CA 549 was more sensitive than the other markers, and cut-off values of 11 and 12 U/ml did not significantly reduce sensitivity. No significant correlation existed between the markers, except for CA 15-3 and CA 549 (r = 0.65). A new quantitative approach to the four markers was effected in the relapsed patients: an X value was calculated for each marker by dividing serum concentration by its cut-off. In these patients, grouped according to the area involved, marker sensitivities were similar except in locoregional relapse, where CA 549 and MCA were the most sensitive. From the data obtained, the more defined cut-off and the good specificity, it is suggested that CA 549 be routinely determined in the follow-up of the disease.

Use of Serum Tumor Markers for the Diagnosis and Follow-Up of Breast Cancer

“…Although CA 15.3 has been reported to be the most sensitive marker in breast cancer [3], in our study TPA, whatever the cutoff used, was the most sensitive marker in breast cancer detection. Only TPA determination odds ratio did not include the unit within the 95% confidence interval, demonstrating a powerful significance in the differential diagnosis of benign and malignant breast conditions ( fig.…”

Prognostic and Predictive Markers in Early Detection of Different Types of Cancers for Selected Organ Sites

“…Several studies have reported that positive serum CEA levels at the time of primary breast cancer diagnosis may represent a negative prognostic parameter [20] and correlate with the stage of disease [21] . Several authors have shown that an increase or a decrease in the CEA levels may reflect the status of disease progression or regression [22].…”

Marqueurs protéiques circulants et cancer du sein

“…Le niveau et la fréquence de l'élévation de ce marqueur sont corrélés avec la progression tumorale [32].…”